Literature DB >> 14519971

Apoptosis induction in HL-60 cells and inhibition of topoisomerase II by triterpene celastrol.

Masahiro Nagase1, Jinsei Oto, Sin Sugiyama, Kouichi Yube, Yoshihisa Takaishi, Nobuo Sakato.   

Abstract

Celastrol, which is a triterpene purified from Celastraceae plants, has anticancer and anti-inflammatory activities. In this study we investigated to clarify whether celastrol can induce apoptosis in a human leukemia HL-60 model system. Celastrol was found to induce apoptosis, and the rank order of the potency of celastrol and its derivatives to induce internucleosomal DNA fragmentation was found to be celastrol>cela-H>>the other derivatives=vehicle control. Many anticancer agents are known to possess the ability to inhibit topoisomerase II, so the inhibitory activities of celastrol and its derivatives on topoisomerase II were also explored. The rank order of the inhibitory activity was found to be celastrol>etoposide>cela-H, indicating that the apoptosis-inducing activities of cela derivatives correspond to their inhibitory activities on topoisomerase II. These data suggested that celastrol may cause its effects such as anticancer activity by the mechanism of apoptosis along with topoisomerase II inhibition.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14519971     DOI: 10.1271/bbb.67.1883

Source DB:  PubMed          Journal:  Biosci Biotechnol Biochem        ISSN: 0916-8451            Impact factor:   2.043


  35 in total

Review 1.  Medicinal chemistry and pharmacology of genus Tripterygium (Celastraceae).

Authors:  Anita M Brinker; Jun Ma; Peter E Lipsky; Ilya Raskin
Journal:  Phytochemistry       Date:  2007-01-23       Impact factor: 4.072

Review 2.  Anticancer Inhibitors of Hsp90 Function: Beyond the Usual Suspects.

Authors:  Gaurav Garg; Anuj Khandelwal; Brian S J Blagg
Journal:  Adv Cancer Res       Date:  2016-02-10       Impact factor: 6.242

3.  Gedunin inactivates the co-chaperone p23 protein causing cancer cell death by apoptosis.

Authors:  Chaitanya A Patwardhan; Abdul Fauq; Laura B Peterson; Charles Miller; Brian S J Blagg; Ahmed Chadli
Journal:  J Biol Chem       Date:  2013-01-25       Impact factor: 5.157

4.  Celastrol regulates multiple nuclear transcription factors belonging to HSP90's clients in a dose- and cell type-dependent way.

Authors:  Denghai Zhang; Limin Xu; Fanfan Cao; Tingxuan Wei; Chunxin Yang; Georges Uzan; Bin Peng
Journal:  Cell Stress Chaperones       Date:  2010-05-18       Impact factor: 3.667

5.  Celastrol increases glucocerebrosidase activity in Gaucher disease by modulating molecular chaperones.

Authors:  Chunzhang Yang; Cody L Swallows; Chao Zhang; Jie Lu; Hongbin Xiao; Roscoe O Brady; Zhengping Zhuang
Journal:  Proc Natl Acad Sci U S A       Date:  2013-12-18       Impact factor: 11.205

6.  Celastrol inhibits Hsp90 chaperoning of steroid receptors by inducing fibrillization of the Co-chaperone p23.

Authors:  Ahmed Chadli; Sara J Felts; Qin Wang; William P Sullivan; Maria Victoria Botuyan; Abdul Fauq; Marina Ramirez-Alvarado; Georges Mer
Journal:  J Biol Chem       Date:  2009-12-08       Impact factor: 5.157

Review 7.  Evolution of NADPH Oxidase Inhibitors: Selectivity and Mechanisms for Target Engagement.

Authors:  Sebastian Altenhöfer; Kim A Radermacher; Pamela W M Kleikers; Kirstin Wingler; Harald H H W Schmidt
Journal:  Antioxid Redox Signal       Date:  2014-02-26       Impact factor: 8.401

8.  The triterpenoid pristimerin induces U87 glioma cell apoptosis through reactive oxygen species-mediated mitochondrial dysfunction.

Authors:  Yan-Yan Yan; Jian-Ping Bai; Yong Xie; Jie-Zhong Yu; Cun-Gen Ma
Journal:  Oncol Lett       Date:  2012-10-22       Impact factor: 2.967

9.  HSP90 inhibitor, celastrol, arrests human monocytic leukemia cell U937 at G0/G1 in thiol-containing agents reversible way.

Authors:  Bin Peng; Limin Xu; Fanfan Cao; Tingxuan Wei; Chunxin Yang; Georges Uzan; Denghai Zhang
Journal:  Mol Cancer       Date:  2010-04-16       Impact factor: 27.401

Review 10.  Natural compounds with proteasome inhibitory activity for cancer prevention and treatment.

Authors:  H Yang; K R Landis-Piwowar; D Chen; V Milacic; Q P Dou
Journal:  Curr Protein Pept Sci       Date:  2008-06       Impact factor: 3.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.